• Recruitment 100% complete for VivaGel^® Phase 2 prevention study for bacterial vaginosis (BV)
• Recruitment for two pivotal Phase 3 BV treatment studies proceeding rapidly with enrolment of the first trial now 100% complete
• Phase 3 treatment trials and the Phase 2 prevention trial all expected to complete in 2H CY2012.
• Activities to support NDA submission, including manufacturing scale up and validation, well advanced

Key points

• > Enrolment passes 60% for VivaGel^® Phase 3 BV treatment trials
• > Trials well on track for completion in 2012
• > One of the trials has already enrolled more than 80% of subjects

BRW Journalist Tony Featherstone profiled Starpharma as the #1 pick of the leading ASX tech stocks in his article, ‘9 hot tech stocks.

The Melbourne-based company is leading a pack of promising biotechs either in, or approaching, phase III trials for US Food and Drug Administration approval. Starpharma’s lead product, VivaGel, is being developed to treat bacterial vaginosis, where the normal balance of bacteria in the vagina is disrupted by an overgrowth of certain bacteria. If approved, VivaGel, a prescription product, would be applied daily to treat bacteria vaginosis and stop it reoccurring.

ABC News’ The Business Presenter Ticky Fullerton interviewed Starpharma CEO Dr Jackie Fairley on Wednesday 30^th May 2012. Ticky discussed Starpharma’s valuable platform technology.

 Read the Transcript (external link)

Starpharma today released its Appendix 4C - Quarterly Cashflow report for the period ended 31 March 2012.

In this issue:

› Starpharma commences pivotal phase 3 VivaGel^® BV treatment trials

› Starpharma continues to build momentum as a leader in the sector

› Starpharma improves efficacy of leading chemotherapy drug docetaxel with dendrimers in breast cancer model

› Nanobiotechnology to reach $6 billion by 2017

Download: Shareholder Update: April 2012 ( pdf file, 1MB)

Jackie Fairley, CEO, talks to BRR Media on the commencement of two concurrent pivotal phase 3 clinical trials of VivaGel® for the treatment of bacterial vaginosis (BV), following receipt of ethics approval.

Listen to the BRR Broadcast (external link)

Melbourne Australia:  Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the commencement of two concurrent pivotal phase 3 clinical trials of VivaGel® for the treatment of bacterial vaginosis (BV), following receipt of ethics approval.

Melbourne, Australia; Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the appointment of Mr Peter Turvey to the Board of Directors.  Mr Turvey recently retired from CSL (ASX:CSL) as Executive Vice President Licensing for the R&D Division and Company Secretary after nearly two decades.

Mr Turvey brings to the Starpharma Board exceptional commercial licensing skills having worked at CSL since 1992 in various roles including Group General Counsel, Company Secretary and Executive Vice President Licensing.

•     CEO Dr Jackie Fairley presenting at the Citi Annual Australian and New Zealand Conference in  London, 6^th March 2012.

•     Premier opportunity to further develop relationships with offshore investors.

•     Starpharma selected as one of only four leading healthcare companies to present alongside 36 ASX listed companies.

View presentation here